Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Alaunos Therapeutics, Inc.TCRT · healthcare
GradeNonecomputable_factors_below_threshold: 5 of 14 inputs computable; 7 are required
Reliability0.76 AUCfailure model, filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate0.60% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size bandunder $12.5M assetstotal assets $3.0M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsshort runway, thin data, degenerate inputsnot computable: dilution, distress, fortress balance sheet
Inputs computable5 of 14
Graded fromfilings received through Apr 30, 2026162 days before the rescan; every figure keyed to the SEC receipt date
Last close$0.792026-10-08; market equity $2.0M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$2$4NovDecJanFebMarAprMayJunJulAugSepOct$0.78
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Mar 21, 2012nonen/aQ2
Mar 21, 2016nonen/aQ3
Feb 21, 2017nonen/aQ2
Mar 21, 2021nonen/aQ3
Apr 21, 2022nonen/aQ2
Apr 21, 2024nonen/aQ1

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 31, 2026; the document on sec.gov.

We are a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. On March 2, 2026, we announced positive preclinical proof-of-concept data for ALN1003 from two separate studies using a standard diet-induced obesity (DIO) mouse model in male C57BL/6 mice maintained on a high-fat diet (60% of calories from fat).

Warnings [top]

Short runway. cash runway is 0.5 months[3]
Thin data. 5 of 14 grade factors are computable; minimum is 7
Degenerate inputs. latest revenue or assets are at or below the $100,000 validity floor[1-2]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 8.9
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(45.7%)[1,4-6](6.6%)8.98112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 82.0
Twelve-month failure probabilitynot computable0.07%
latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime(1,020.47)[1,7-12](0.31)100.07562025-12-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio2.45x[7-8]2.96x64.08392025-12-31
Growth and financing, sleeve percentile 99.5
Revenue growth, three-year compound(88.0%)[2,13-15]10.0%99.84152025-12-31
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
one or more required annual facts are missing
Asset growth, three years(64.3%)[1,6,16-17]2.1%99.17042025-12-31
Net share issuance, one yearnot computable2.5%
prior share count is 30 days earlier

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(29.5%)8.0%25hotter than 25 of 100 peers
Distance from 52-week high(82.1%)(31.4%)8closer to its high than 8 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yield(149.5%)(1.0%)4pricier than 96 of 100 peers
Book value to price0.330.2855pricier than 45 of 100 peers
Sales to price0.000.314pricier than 96 of 100 peers
Composite equity issuance, five years57.4%20.3%67more equity-funded than 67 of 100 peers
Relative strength against the sector, log excess return(0.56)(0.14)25ahead of 25 of 100 peers

Inputs: market equity $2.0M; EBIT -$4.2M; free cash flow -$3.0M; book equity $652,000; sales $5,000; cash $124,000[18].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(151.6%)✗ fail[4,6]
Operating cash flow above zero-$2.9M✗ fail[5]
Return on assets improved(95.0 pts)✗ fail[4,6,16,19]
Operating cash flow exceeds net income$1.3M✓ pass[4-5]
Long-term leverage felln/a[1,6,16,20]
Current ratio improved(153.6 pts)✗ fail[7-8,21-22]
No new shares issuedn/a[23-24]
Gross margin improvedn/a
Asset turnover improved0.1 pts✓ pass[2,6,13,16]
Cash, filings, liquidity
Cash and equivalents$124,000[3]
Operating cash flow, four quarters-$2.7M[3,5,25-28]
Months of runway0.5
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing56
10-Q received Aug 14, 2026
Median daily dollar volume$22,476
63 sessions
Days since newest grade input162

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$3.0M2025-12-312026-03-3110-Kfiling · viewer · series
2revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$5,0002025-12-312026-03-3110-Kfiling · viewer · series
3cashus-gaap:CashAndCashEquivalentsAtCarryingValue$124,0002026-06-302026-08-1410-Qfiling · viewer · series
4net incomeus-gaap:NetIncomeLoss-$4.2M2025-12-312026-03-3110-Kfiling · viewer · series
5operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$2.9M2025-12-312026-03-3110-Kfiling · viewer · series
6assetsus-gaap:Assets$2.8M2024-12-312026-03-3110-Kfiling · viewer · series
7current assetsus-gaap:AssetsCurrent$2.0M2025-12-312026-03-3110-Kfiling · viewer · series
8current liabilitiesus-gaap:LiabilitiesCurrent$813,0002025-12-312026-03-3110-Kfiling · viewer · series
9retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$924.6M2025-12-312026-03-3110-Kfiling · viewer · series
10operating incomeus-gaap:OperatingIncomeLoss-$4.2M2025-12-312026-03-3110-Kfiling · viewer · series
11book equityus-gaap:StockholdersEquity$2.2M2025-12-312026-03-3110-Kfiling · viewer · series
12liabilitiesus-gaap:Liabilities$813,0002025-12-312026-03-3110-Kfiling · viewer · series
13revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$10,0002024-12-312026-03-3110-Kfiling · viewer · series
14revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$5,0002023-12-312025-03-3110-Kfiling · viewer · series
15revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$2.9M2022-12-312024-04-0110-Kfiling · viewer · series
16assetsus-gaap:Assets$8.3M2023-12-312025-03-3110-Kfiling · viewer · series
17assetsus-gaap:Assets$64.9M2022-12-312024-04-0110-Kfiling · viewer · series
18shares outstandingdei:EntityCommonStockSharesOutstanding2,540,4802026-08-142026-08-1410-Qfiling · viewer · series
19net incomeus-gaap:NetIncomeLoss-$4.7M2024-12-312026-03-3110-Kfiling · viewer · series
20long term debtus-gaap:LongTermDebtNoncurrent$02024-12-312025-03-3110-Kfiling · viewer · series
21current assetsus-gaap:AssetsCurrent$2.8M2024-12-312026-03-3110-Kfiling · viewer · series
22current liabilitiesus-gaap:LiabilitiesCurrent$692,0002024-12-312026-03-3110-Kfiling · viewer · series
23shares outstandingdei:EntityCommonStockSharesOutstanding2,402,3722026-04-302026-04-3010-K/Afiling · viewer · series
24shares outstandingdei:EntityCommonStockSharesOutstanding2,378,2532026-03-312026-03-3110-Kfiling · viewer · series
25operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$1.3M2026-06-302026-08-1410-Qfiling · viewer · series
26operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$1.0M2026-03-312026-05-1510-Qfiling · viewer · series
27operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$2.3M2025-09-302025-11-1410-Qfiling · viewer · series
28operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$1.5M2025-06-302026-08-1410-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.